BIVI - Prothena BioVie among decliners after Biogen data for new Alzheimer's therapy
2023-10-26 13:48:39 ET
More on BioVie, Cognition, etc.
- BioVie: Bullish Signals From Blinded Data Presentation (Rating Upgrade)
- Prothena: Switching From 'Hold' To 'Buy' On Lead Alzheimer's Drug Promise
- BioVie: Well-Powered Phase 3 Trial In Alzheimer's Could Greatly Benefit Investors
- Prothena jumps on report company may explore a potential sale
- BioVie perks up on trial update for Alzheimer’s candidate
For further details see:
Prothena, BioVie among decliners after Biogen data for new Alzheimer’s therapy